Who is sponsoring NCT05195216?

NCT05195216 is sponsored by Elif Kabasakal.

What condition does NCT05195216 study?

NCT05195216 studies Cystic Fibrosis.

Is NCT05195216 still recruiting?

NCT05195216 is currently completed. Last updated 18 January 2022.

Last reviewed 2022-01-18 · How we verify

NCT05195216

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psychosocial Factors and Quality of Life in the Effect of Fear of COVID-19 With Cystic Fibrosis

Completed Last updated 18 January 2022

What this trial tests

trial testing Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form in Cystic Fibrosis in 128 participants. Completed in 25 December 2021.

Timeline

20 November 2021

Primary endpoint
30 November 2021

25 December 2021

Quick facts

Lead sponsor	Elif Kabasakal
Status	Completed
Study type	OBSERVATIONAL
Enrollment	128
Start date	20 November 2021
Primary completion	30 November 2021
Estimated completion	25 December 2021
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Elif Kabasakal

Who can join

16 and older, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study; The COVID-19 pandemic is to investigate the effects of COVID-19 fear levels of patients with cystic fibrosis on the psychosocial and quality of life levels of individuals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Other Elif Kabasakal trials

Trials by the same sponsor.

NCT07188675 — Functional Inspiratory Training in Bronchiectasis · NA · recruiting
NCT07012967 — Kinesio Taping in Obesity: Breathing and Sleep Implications · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05195216 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Elif Kabasakal
Last refreshed: 18 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05195216.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing